CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers
View ORCID ProfileApril A. N. Rose, Jennifer Maxwell, Emmanuelle Rousselle, Melody Riaud, View ORCID ProfileIslam E. Elkholi, Chantel Mukonoweshuro, Marco Biondini, Erica Cianfarano, Isabel Soria-Bretones, Chantal Tobin, Meghan McGuire, Ian King, Tong Zhang, Trevor J. Pugh, Zaid Saeed Kamil, Frances A. Shepherd, Natasha Leighl, Albiruni Abdul Razak, Aaron Hansen, Sam Saibil, Philippe Bedard, Peter M. Siegel, View ORCID ProfileLillian L. Siu, David W. Cescon, View ORCID ProfileAnna Spreafico
doi: https://doi.org/10.1101/2024.07.28.24311101
April A. N. Rose
1Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
3Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada
4Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Jennifer Maxwell
2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
4Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC
Emmanuelle Rousselle
2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
4Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC
Melody Riaud
1Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
Islam E. Elkholi
1Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
Chantel Mukonoweshuro
2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
4Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC
Marco Biondini
6Goodman Cancer Institute, McGill University, Montreal, QC
Erica Cianfarano
7Integrated Program in Neuroscience, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Montreal, QC
Isabel Soria-Bretones
1Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
2Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Chantal Tobin
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Meghan McGuire
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Ian King
8Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada
9Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Tong Zhang
8Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada
9Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Trevor J. Pugh
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
10Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
11Ontario Institute for Cancer Research, Toronto, Canada
Zaid Saeed Kamil
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
9Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Frances A. Shepherd
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Natasha Leighl
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Albiruni Abdul Razak
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Aaron Hansen
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Sam Saibil
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Philippe Bedard
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Peter M. Siegel
1Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada
6Goodman Cancer Institute, McGill University, Montreal, QC
13Department of Biochemistry, McGill University, Montreal, QC
14Department of Anatomy and Cell Biology, McGill University, Montreal, QC
Lillian L. Siu
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
David W. Cescon
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Anna Spreafico
5Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
12Division of Medical Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted July 29, 2024.
CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers
April A. N. Rose, Jennifer Maxwell, Emmanuelle Rousselle, Melody Riaud, Islam E. Elkholi, Chantel Mukonoweshuro, Marco Biondini, Erica Cianfarano, Isabel Soria-Bretones, Chantal Tobin, Meghan McGuire, Ian King, Tong Zhang, Trevor J. Pugh, Zaid Saeed Kamil, Frances A. Shepherd, Natasha Leighl, Albiruni Abdul Razak, Aaron Hansen, Sam Saibil, Philippe Bedard, Peter M. Siegel, Lillian L. Siu, David W. Cescon, Anna Spreafico
medRxiv 2024.07.28.24311101; doi: https://doi.org/10.1101/2024.07.28.24311101
CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancers
April A. N. Rose, Jennifer Maxwell, Emmanuelle Rousselle, Melody Riaud, Islam E. Elkholi, Chantel Mukonoweshuro, Marco Biondini, Erica Cianfarano, Isabel Soria-Bretones, Chantal Tobin, Meghan McGuire, Ian King, Tong Zhang, Trevor J. Pugh, Zaid Saeed Kamil, Frances A. Shepherd, Natasha Leighl, Albiruni Abdul Razak, Aaron Hansen, Sam Saibil, Philippe Bedard, Peter M. Siegel, Lillian L. Siu, David W. Cescon, Anna Spreafico
medRxiv 2024.07.28.24311101; doi: https://doi.org/10.1101/2024.07.28.24311101
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)